Eli Lilly (LLY) Acquires Vaccine Firms for $3.8 Billion Growth Strategy

Eli Lilly (LLY) reported approximately $12.8 billion in revenues for Q1 2026, with its key drugs Mounjaro and Zepbound experiencing year-over-year sales growth of 125% and 80%, respectively. The company has invested $3.8 billion to acquire Curevo, LimmaTech Biologics AG, and Vaccine Company to expand its presence in infectious diseases. Eli Lilly's current P/E ratio stands at 39x, significantly higher than the pharmaceutical sector average of 24x. This strategic move is seen as a way to diversify its portfolio as the patent protection on its GLP-1 drugs is time-limited.